Article

Collagen CXL in young keratoconic patients

Collagen crosslinking (CXL) provides good results in young patients with keratoconus, but the key to success in these young patients is rapid treatment upon presentation without waiting for disease progression, said Paolo Vinciguerra, MD.

Boston-Collagen crosslinking (CXL) provides good results in young patients with keratoconus, but the key to success in these young patients is rapid treatment upon presentation without waiting for disease progression, said Paolo Vinciguerra, MD.

“Don’t wait to treat,” advised Dr. Vinciguerra, Clinica Oculistica, Milan.

He reported a case in which a 12-year-old patient lost 186 µm of corneal thickness after only 4 months because collagen CXL had not been applied.

In addition to stopping disease progression, young patients frequently have substantial improvements in the best-corrected and uncorrected visual acuity levels after treatment, however, there is less reduction in cylinder, he said.

Dr. Vinciguerra also noted that young patients have a faster visual recovery after CXL treatment. The change in visual acuity 1 year postoperatively was similar to that in adult patients 2 years postoperatively.

 

In his experience with 66 patients with keratoconus treated with collagen CXL thus far, Dr. Vinciguerra said his take-home points are that collagen CXL halts progression of keratoconus, patients have a significant increase in their best-corrected visual acuity, and the group that achieves the best improvement is between the ages of 18 and 39 years.

“My suggestion is do not wait to treat until progression becomes evident,” Dr. Vinciguerra said. “Collagen crosslinking is safe. Careful patient screening is necessary. Frequently, patients present with an advanced stage of keratoconus. Young patients should undergo topography early.”

 

For more articles in this issue of Ophthalmology Times’ Conference Brief, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.